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Abstract
Molecular studies have demonstrated that mutations in the Plasmodium falciparum chloroquine resistance transporter gene
(Pfcrt) play a major role in chloroquine resistance, while mutations in P. falciparum multidrug resistance gene (Pfmdr-1) act
as modulator. In Madagascar, the high rate of chloroquine treatment failure (44%) appears disconnected from the overall
level of in vitro CQ susceptibility (prevalence of CQ-resistant parasites ,5%) or Pfcrt mutant isolates (,1%), strongly
contrasting with sub-Saharan African countries. Previous studies showed a high frequency of Pfmdr-1 mutant parasites
(.60% of isolates), but did not explore their association with P. falciparum chloroquine resistance. To document the
association of Pfmdr-1 alleles with chloroquine resistance in Madagascar, 249 P. falciparum samples collected from patients
enrolled in a chloroquine in vivo efficacy study were genotyped in Pfcrt/Pfmdr-1 genes as well as the estimation of the
Pfmdr-1 copy number. Except 2 isolates, all samples displayed a wild-type Pfcrt allele without Pfmdr-1 amplification.
Chloroquine treatment failures were significantly associated with Pfmdr-1 86Y mutant codon (OR=4.6). The cumulative
incidence of recurrence of patients carrying the Pfmdr-1 86Y mutation at day 0 (21 days) was shorter than patients carrying
Pfmdr-1 86N wild type codon (28 days). In an independent set of 90 selected isolates, in vitro susceptibility to chloroquine
was not associated with Pfmdr-1 polymorphisms. Analysis of two microsatellites flanking Pfmdr-1 allele showed that
mutations occurred on multiple genetic backgrounds. In Madagascar, Pfmdr-1 polymorphism is associated with late
chloroquine clinical failures and unrelated with in vitro susceptibility or Pfcrt genotype. These results highlight the limits of
the current in vitro tests routinely used to monitor CQ drug resistance in this unique context. Gaining insight about the
mechanisms that regulate polymorphism in Pfmdr1 remains important, particularly regarding the evolution and spread of
Pfmdr-1 alleles in P. falciparum populations under changing drug pressure which may have important consequences in
terms of antimalarial use management.
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Introduction
Plasmodium falciparum resistance to chloroquine (CQ) has
emerged at least from six independent foci (South East Asia,
Venezuela, Colombia, Papua New Guinea, India and Philippines)
in the late 1950s and in the 1960s [1,2,3]. Molecular evolutionary
studies have demonstrated that P. falciparum CQ-resistant parasites
from South-East Asia have entered in East Africa (Kenya and
Tanzania) in the late 1970s and spread across the African
continent within two decades [2]. P. falciparum-related deaths rose
sharply after the spread of CQ-resistant parasites in sub-Saharan
Africa, affecting mostly children under 5 years of age [4,5,6].
CQ-resistance in P. falciparum shows some biological similarities
with the multiple drug resistance phenotype of mammalian
tumour cells, as both involve expulsion of drug out of the cytosol
of the cell and can be reversed by calcium channel antagonists
such as verapamil [7]. Based on molecular allele exchange studies
and analysis of genetic crosses, it is today generally accepted that
the major role in CQ resistance is determined by polymorphisms
in Pfcrt, a gene encoding a transporter which promotes, in its
mutated forms, drug efflux from the parasite digestive vacuole,
while Pfmdr-1 modulates the level of in vitro CQ-resistance [3,8,9].
In addition, mutations or amplifications of Pfmdr-1 gene can play a
significant role in P. falciparum resistance to diverse antimalarials
such as mefloquine, quinine or artemisinin derivatives [10].
Specific combinations of Pfcrt and Pfmdr-1 alleles, resulting in
varying responses to CQ (and amodiaquine), appeared geograph-
ically restricted, which may explain why some field studies
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13281reported an association between Pfmdr-1 polymorphisms and CQ
resistance and other studies did not [9].
In Madagascar, CQ was first introduced in 1945 and was largely
used during more than 50 years, in particular in a campaign for
malaria prevention treatment in children [11]. A shortage in CQ
supply in the 1970s was followed by a large-scale epidemic in the
late 1980s. Wide-scale access to CQ treatment resumed afterwards,
and CQ is still used today though its replacement by the artesunate
plusamodiaquine combination therapy is recommended as first-line
treatment for uncomplicated cases since 2005. The first clinical
cases of CQ resistance were suspected in 1975. In 1981, other cases
of treatment failures were reported and in vitro tests showed isolates
with high 50% inhibitory concentration for CQ (IC50) indicative of
in vitro CQ-resistance. However, during the 1981-2008 period,
several studies outlined lower rates of in vitro CQ-resistance and
therapeutic failures in Madagascar than in other African countries
[11]. Currently, the prevalence of in vitro CQ resistance does not
exceed 5% of isolates and Pfcrt mutant parasites are found in less
than 1% of collected isolates [12]. Surprisingly, these figures appear
disconnected from the high level of clinical treatment failures (44%)
[13], most of which (,90%) are late clinical/parasitological
treatment failures. Interestingly, previous surveys outlined the
presence of Pfmdr-1 mutations in more than 60% of isolates,
suggesting that Pfmdr-1mutants could be responsible forCQ clinical
failure in Madagascar.
The aim of the present work was to document the association of
Pfmdr-1 with in vivo CQ clinical failure and in vitro CQ resistance. To
this end, two independent sets of P. falciparum samples collected in
2006–2007 from in vivo and in vitro susceptibility studies were
genotyped for Pfcrt and Pfmdr1 g e n e sa sw e l la st h ee s t i m a t i o no ft h e
Pfmdr-1 copy number. Isolates that meet the inclusion criteria were
included in the association analysis (240 from in vivo study and 90
from in vitro testing). In addition, the evolutionary dynamics of the
Pfmdr-1 locus in the Malagasyparasite populations werealso assessed.
Our data show that in this particular setting, Pfmdr-1 polymorphism
onmultiplegeneticbackgrounds,inabsenceofmutationsinPfcrtgene
or Pfmdr-1 gene amplification was significantly associated with late
chloroquine clinical failures and unrelated with the overall level of in
vitro CQ susceptibility, raising the limits of the current in vitro tests
routinely used to monitor CQ drug resistance.
Materials and Methods
Study Sites
P. falciparum samples from eight sentinel sites involved in the
monitoring of the antimalarial drug resistance in Madagascar [12]
were studied. The collection sites were located in the four main
malarious epidemiological strata: Ejeda and Ihosy in the South
(sub-desert stratum, epidemic prone), Maevatanana and Mian-
drivazo in the West (tropical stratum, seasonal and endemic area),
Tsiroanomandidy and Moramanga in the foothills of the Central
Highlands (highlands stratum, low-endemic area) and Farafan-
gana and Andapa in the East (equatorial stratum, perennial
endemic area). Malaria transmission, estimated by annual
entomological inoculation rate (EIR, number of bites of infected
anophelines per person sleeping indoors), varied according to the
sites from 0.2 (in the South) to 240 (in the East) [14]. The
prevalence of anti-MSP1 antibodies used as proxy of the burden of
malaria in each site was previously determined at the same
collection period [15] and were included in our analysis.
Patients and in vivo study
In 2006–2007, multi-site prospective chemotherapeutic studies
were carried out for assessing the therapeutic efficacy of
antimalarial therapies recommended by the National Malaria
Control Programme (NMCP) (registration number ISRCTN-
36517335) [13]. Patients with microscopically confirmed uncom-
plicated P. falciparum malaria were randomized into one of the four
treatment groups: Chloroquine (CQ), Amodiaquine (AQ), Sulfa-
doxine-Pyrimethamine association (SP) and Artesunate-Amodia-
quine combination (ASAQ). According to the 2003 WHO
protocol, patients aged from six months to 15 years, presenting
with P. falciparum monoinfection (parasitaemia from 1,000 to
200,000/mL), axillary temperature $37.5uC, body weight .5 kg,
haemoglobin (Hb) $5 g/dL, without severe malnutrition, signs of
severity, or a concomitant disease were included in the clinical
trial. Once written informed consent was given by the patient or
the guardian and after randomization, patients were administered
either CQ (10 mg/kg on days 0 and 1, and 5 mg/kg on day 2),
AQ (10 mg/kg on days 0, 1, and 2), SP (25 mg/kg sulfadoxine and
1.25 mg/kg pyrimethamine as a single dose on day 0) or ASAQ
(AS: 4 mg/kg on days 0, 1, and 2 and AQ:10 mg/kg on days 0, 1,
and 2) and seen on days 1, 2, 3, 7, 14, 21 and 28, or any
intervening day if they were unwell for malaria infection to assess
the clinical and parasitological efficacy of the drug regimens.
Blood samples were obtained by finger prick on the enrolment and
all follow-up days including any unscheduled day to use for
analysis of thick and thin blood smears and for storage on filter
paper for further molecular analysis. Haemoglobin concentration
was measured on day 0 using a HemoCue haemoglobinometre
(HemoCue AB, A ¨ngelholm, Sweden).
Collection of P. falciparum isolates for in vitro drug
sensitivity testing
As part of the surveillance of antimalarial drug resistance in
Madagascar, fresh P. falciparum clinical isolates were routinely
collected in 2006–2007 from symptomatic patients prior to
treatment in six of the eight sites (Ihosy, Maevatanana,
Miandrivazo, Tsiroanomandidy, Moramanga and Farafangana).
Venous blood samples were collected in tubes coated with EDTA
(Vacutainer tubes, Becton Dickinson, Rutherford, NJ, USA), from
malaria-positive patients (.2 years old) after they gave their
consent for participation in the study (approval number 007/
SANPF/2007). Presence of malaria parasites was evaluated by
using a rapid diagnostic test based on the detection of Plasmodium-
specific lactate dehydrogenase (pLDH) (OptiMAL-IT, DiaMed
AG, Cressier sur Morat, Switzerland). Positive patients were
treated with the artesunate-amodiaquine combination, according
to the National Malaria Control Programme (NMCP), and
samples were sent to the Malaria Research Unit of the Institut
Pasteur of Madagascar in a controlled cool box at 4uC. Drug
sensitivity assays were done using the classical isotopic 48-h test, as
described [12], on blood samples with parasitaemia $0.1%,
available within 48 h after blood collection and from patients
declaring no antimalarial drug intake during the previous 7 days.
For CQ sensitivity assay, three control wells without drug were
used as control and each concentration ranging from 12.5 to
1,600 nM was studied in duplicate or triplicate. The IC50, i.e. the
drug concentration corresponding to 50% of
3H-hypoxanthine
uptake by the parasites in drug-free control wells, was determined
by probit/logit regression analysis. The quality of the assays was
controlled by using P. falciparum reference lines (3D7 Africa, CQ-
sensitive clone and FCM29 Cameroon, CQ-resistant clone).
DNA extraction
Parasite DNA was available from whole blood or capillary
blood transferred to filter paper (Whatman, Maidstone, UK).
DNA was extracted from blood spots with InstageneH Matrix resin
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manufacturer’s instructions or directly from 100 ml of whole blood
by using the phenol-chloroform method [16]. Parasite species was
confirmed by using real-time polymerase chain reaction as
described by de Monbrison et al. [17].
Pfmdr-1 and Pfcrt genotyping in isolates from day 0 and
day of recurrence
Pfmdr-1 and Pfcrt genes were amplified in samples from
enrolment (and day of recurrence in cases of CQ treatment
failure) by nested PCR approach, as described [12]. For Pfmdr-1
gene, two fragments (549 bp, from codons 23 to 206 and 938 bp,
from codons 966 to 1278) and for Pfcrt gene, three fragments
(450 bp, from codon 37 in exon 2 to codon 125 in exon 3, 447 bp,
from codon 121 in exon 3 to codon 211 in exon 4 and 850 bp,
from codon 199 in exon 3 to codon 316 in exon 7) were
sequenced. Sequencing reactions were carried out with ABI Prism
BigDye Terminator cycle sequencing ready reaction kit and were
run on a model 3730 xl genetic analyzer (Applied Biosystems,
Courtaboeuf, France). Electrophoregrams were visualized and
analyzed with CEQ2000 genetic analysis system software (Beck-
man Coulter, Villepinte, France) and amino acid sequences were
compared with the wild-type amino acid sequences (GenBank
accession numbers, AF030694 for Pfcrt, and XM_001351751 for
Pfmdr-1). The presence of single nucleotide polymorphisms (SNPs)
was confirmed by reading both strands. Sequences of insufficient
quality were either resequenced or rejected. Pfmdr-1 and Pfcrt
alleles were reconstructed from full sequences presenting an
unambiguous single allele signal at each nucleotide position.
Pfmdr-1 copy number determination
The Pfmdr-1 copy number was measured by TaqMan real-time
PCR (Rotor-Gene 6000, Corbett Research, Sydney, Australia)
relative to the single copy of the ß-tubulin (used as a housekeeping
gene), as described [12]. All samples were run in duplicate in
25 mL reaction mixtures. For each run, the Pfmdr-1 copy number
was measured relative to the numbers in two standard calibrator
parasite clonal lines (3D7 Africa and Dd2), by the DDCT method
[18]. Reference DNA clone W2 (which has three copies of Pfmdr-1)
was used as the quality control in each run.
Analysis microsatellite flanking Pfmdr-1
Two microsatellite markers (MS loci 956456 and 957861),
located on chromosome 5 and extending ,10 kb downstream the
Pfmdr-1 gene were used to determine the evolutionary history of
Pfmdr-1 alleles. Microsatellite polymorphism was analyzed using a
nested PCR strategy, as previously described by Mehlotra et al.
[9]. Microsatellite PCR products were genotyped on the basis of
size, using a GeneScan 500 LIZ size standard on an ABI Prism
3730 XL DNA analyzer.
Assessment of isolate clonality
The number of genotypes present in isolates collected from in
vivo and in vitro assays, was estimated by using an allelic family-
specific nested PCR (MAD20, K1, and RO33 for Pfmsp-1 and
3D7 Africa and FC27 for Pfmsp-2) [12]. Clonality was defined as
the highest number of alleles detected at either of the two loci and
used to classify isolates as monoclonal or polyclonal and to
distinguish recrudescence from new infection for all patients failing
therapy after day 7 (isolates from day 0 and day of recurrence). All
PCR amplifications contained a positive control (genomic DNA
from strains W2, HB3, and 3D7 Africa) and a negative control (no
target DNA).
Statistical analysis
Data were entered and verified using Microsoft Excel

software, and analyzed using EpiInfo 6.04
 software (Centers
for Disease Control and Prevention, Atlanta, GA, United States)
and XLSTAT
 for Windows XP (Addinsoft, Paris, France). For in
vivo clinical trial samples, criteria of inclusion for the analysis were
(i) patients with complete 28-days follow-up, (ii) absence of
reinfection, (iii) wild-type Pfcrt alleles in isolates collected at day
0 and day of recurrence and (iv) successful determination of Pfmdr-
1 alleles in isolates from day 0 and day of recurrence. For in vitro
testing samples, criteria of inclusion for the analysis were (i)
monoclonal isolates by using msp1/msp2 genotyping, (ii) wild-type
Pfcrt alleles and (iii) successful determination of Pfmdr-1 alleles.
The Mann-Whitney U test or Kruskal-Wallis method were used
for non-parametric comparisons, and Student’s t test or one-way
analysis of variance for parametric comparisons. For categorical
variables, Chi-squared or Fisher’s exact tests were used to assess
significant differences in proportions. Odds ratios (OR) and their
95% confidence intervals (95%CI), describing the association
between CQ clinical outcomes and exposure variables were
determined by conditional logistic regression.
For the multivariate analysis, variables with P-values ,0.25
were initially introduced into the model and removed following a
backwards-stepwise selection procedure to leave only those with a
P-value ,0.05 in the final model. The relation between Pfmdr-1
86Y mutation in isolates from day of recurrence and clinical
response to CQ treatment was assessed by survival analysis using
the Kaplan-Meier method and the log-rank test. The median
asexual parasite densities clearance time (in percent of value on
day 0) was also compared between patients according to the
Pfmdr-1 alleles (86N and 86Y) found at day 0 (and day of
recurrence). All reported P-values are two-sided and were
considered statistically significant if less than 0.05.
Genetic diversity was assessed by Nei’s unbiased expected
heterozygosity (He) from haploid data and calculated as He=[n/
(n21)][12pi] (n=the number of isolates sampled; pi=the
frequency of the i
th allele [19]. Population genetic differentiation
was measured using Wright’s F statistics [20]; population genetic
parameters were computed with FSTAT software, v2.9.4 [21].
Ethical approval
The study protocol was reviewed and approved by the Ethics
Committee of the Ministry of Health of Madagascar (approval
number 007/SANPF/2007; registration number ISRCTN-
36517335). Informed written consent was provided by all patients
or their parents/guardians before inclusion in the study.
Results
In vivo and in vitro sample collection
In the in vivo clinical trial, a total of 8363 febrile children
attending in health centres from the sentinel sites were screened for
falciparum malaria and 1873 were microscopically positive for P.
falciparum. They were assigned in different treatment groups.
Among the 320 patients treated with CQ, 240 of them (75%) met
the study analysis criteria. According to the WHO 2003 protocol,
119 patients were classified as cured and 121 as failing treatment
(13 patients failed before day 7, 20 patients between days 8–14, 46
patients between days 15–21 and 42 patients between days 22–28).
Late treatment failures accounted for 89.3% of the overall
treatment failures. Details are given in figure 1.
Among the 420 P. falciparum isolates tested for in vitro
susceptibility to CQ, 372 (88.6%) were successfully assayed. All
isolates presented a wild type Pfcrt allele; ninety of them, meeting
CQ Resistance in Madagascar
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the 90 isolates in vitro tested, the geometric mean and the median
of CQ IC50 was 18.7 nM (95%CI 14.7–23.7 nM) and 22 nM
(95%CI 16.2–25.0 nM), respectively.
Pfmdr-1 alleles, copy number of Pfmdr-1 gene
Pfmdr-1 alleles were determined for the 240 isolates from the in
vivo efficacy study (day 0 and day of recurrence, when available)
and for 90 isolates for which the IC50 for CQ was determined.
Amongst in vivo isolates, three of five major SNPs previously
related to CQ-resistance were observed at day 0, N86Y (147/240,
61.2%), Y184F (172/240, 71.7%), and D1246Y (80/240, 33.3%),
present in eight different alleles: the wild-type allele NYD (11.2%),
three single-mutant alleles (NFD, 22.9%; YYD, 14.6% and NYY,
1.2%), three double-mutant alleles (YFD, 17.9%; NFY, 3.3% and
YYY, 1.2%) and one triple-mutant allele (YFY, 27.5%).
Discordant alleles were found in 24 isolates between isolate from
day 0 (wild-type NYD) and isolate from day of recurrence (13
single-mutant alleles YYD, 8 single-mutant alleles NFD and 3
double-mutant alleles YFD). There was a non-random association
between the N86Y and D1246Y loci (R
2=0.23, P=0.004) and
F184Y and D1246Y loci (R
2=0.28, P=0.0003).
Amongst in vitro isolates, only three isolates had an
IC50.100 nM: one triple-mutant allele (YFY,I C 50=142 nM),
one double-mutant allele (YFD, IC50=126 nM) and one single-
mutant allele (NFD, IC50=140 nM). Comparison of geometric
mean IC50 between isolates harbouring different Pfmdr-1 alleles
showed no significant difference: 18.0 nM (n=37, 95%CI 12.1–
26.6 nM) in Pfmdr-1 86N isolates compared to 19.2 nM (n=53,
95%CI 14.1–26.0 nM) in Pfmdr-1 86Y isolates, 14.3 nM (n=72,
95%CI 8.2–25.0 nM) in Pfmdr-1 184Y isolates compared to
20.0 nM (n=18, 95%CI 15.3–26.1 nM) in Pfmdr-1 184F isolates
and 21.4 nM (n=61, 95%CI 13.5–36.7 nM) in Pfmdr-1 1246D
isolates compared to 18.6 nM (n=21, 95%CI 12.3–28.3 nM) in
Pfmdr-1 1246Y isolates.
The Pfmdr-1 copy number was determined for 290 isolates (219
from in vivo studies and 71 from in vitro assays). The mean copy
number was 0.93 (ranging from 0.74 to 1.33). When the value was
rounded to the nearest integer, no Pfmdr-1 amplification was
observed.
Figure 1. Flowchart of patients. Flowchart of patients: Enrollment, Randomization, Follow-up, Molecular genotyping.
doi:10.1371/journal.pone.0013281.g001
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The polymorphisms in two microsatellite loci flanking the wild-
type coding sequence and mutant-type alleles (single-mutants to
triple-mutant) are shown in Figure 2. The MS locus 956456 had 6
alleles (ranging from 210 to 228 bp) and the MS locus 957861 had
4 alleles (ranging from 179 to 185 bp), displaying 7 different
haplotypes. Microsatellite markers were moderately polymorphic
for wild- and mutant-type alleles with a mean Nei’s unbiased
expected heterozygosity (He) ranging from 0.26 (NFY) to 0.66
(NYD). The Wright’s fixation index analysis showed a significant
absence of genetic differentiation between allele populations.
In vivo outcomes and risk factors associated to CQ
treatment failure
To test whether any collected variables (ecological environment,
patients and isolates characteristics) were associated with clinical
response to CQ treatment, we compared them between both
cured- and failing treatment patient groups (Table 1). Among
these, four variables were significantly associated with the risk of
CQ treatment failure: (i) prevalence of anti-PfMSP-1 antibodies
previously estimated in the site (P=0.04, 1.8-fold increased risk of
CQ treatment failures in area of unstable malaria), (ii) age group
(P,0.0001, increased risk of CQ clinical failures inversely
correlated to age: 1.6-fold in the 6–10 years age group and 4.5-
fold in the 0.5–5 years age group), (iii) haemoglobin concentration
at day 0 (P,0.0002, 2.4-fold increased risk of CQ treatment
failures for people with haemoglobin concentration ,10 g/dL at
day 0) and (iv) presence of the Pfmdr-1 86Y mutation in isolates
collected on day 0 (P=0.009, 2-fold increased risk of CQ
treatment failures) or on day of recurrence (P,0.0001, 4.2-fold
increased risk of CQ treatment failures).
In the multivariate analysis, variables with P-values ,0.25 were
initially introduced into the model (prevalence of anti-PfMSP-1
antibodies, gender, age, haemoglobin concentration at day 0,
multiplicity of infection, presence of Pfmdr-1 codon mutation at
position 86 in isolates from day 0 and day of recurrence and at
position 184 in isolates from day of recurrence). Following a
backwards-stepwise selection procedure, CQ treatment failures
were significantly associated with presence of Pfmdr-1 codon
mutation at position 86 in the parasites collected on day of
recrudescence (OR=4.6, 95%CI 2.3 to 8.9, P,0.0001), age
(OR=1.2, 95%CI 1.1 to 1.3, P=0.0002) and prevalence of
antiPfMSP-1 antibodies (OR=1.02, 95%CI 1.0 to 1.05, P=0.02).
Asexual parasite clearance following CQ-treatment displayed
significant differences according to Pfmdr-1 allelic form at position
86 at day 1 (Pfmdr-1 86N: 77.1%, n=89 and Pfmdr-1 86Y: 95.3%,
n=151, P=0.0001), day 7 (Pfmdr-1 86N: 3.7%, n=85 and Pfmdr-
1 86Y: 34.3%, n=142, P,0.0001) and day 14 (Pfmdr-1 86N:
2.0%, n=78 and Pfmdr-1 86Y: 54.9%, n=129, P,0.0001)
(Figure 3).
Cumulative incidence of recurrence of patients and
Pfmdr-1 86 mutation
The relation between Pfmdr-1 86Y mutation in isolates from day
0 (or day of recrudescence, if available) and clinical response to
CQ treatment by using the time of recurrence, showed a markedly
difference between the two curves (Figure 4). The cumulative
incidence of recurrence of patients carrying the Pfmdr-1 86Y allele
(n=163, median time of recurrence 21 days) was significantly
shorter than patients carrying Pfmdr-1 86N (n=77, median time of
recurrence 28 days). The log-rank test shows that the two curves
differ significantly (P,0.0001) and the Pfmdr-1 N86Y allele had a
significant influence on the time of recurrence. The hazard ratio
comparing the hazards in the two groups was estimated at 0.36
(95%IC: 0.23–055).
Discussion
In the isolates from Madagascar studied here which harboured
a wild type Pfcrt, Pfmdr-1 polymorphism, in the absence of any
noticeable gene amplification, seems to play a major role in late
chloroquine clinical failures without affecting the overall level of in
vitro CQ susceptibility. This situation contrasts with findings from
multiple settings across the African continent, where CQ
resistance depends primarily on mutations in Pfcrt gene and on
additional mutations in Pfmdr-1 gene, which may increase the level
of resistance afforded by Pfcrt. Pfcrt mutant alleles seem universally
found, albeit with different haplotypes in different geographical
regions [22]. The association of Pfmdr-1 with CQ resistance was
not found in some areas [10], possibly reflecting the fact that the
impact of the Pfcrt/Pfmdr-1 combination mutation depends on the
genetic background of the strain [23,24] as demonstrated by
studies with genetically manipulated lines or recombinant progeny
of experimental crosses [23,24] and the history of use of the
antimalarial drugs (chloroquine and quinine being the two mains
drugs used in Madagascar).
The observation that parasites with a wild Pfcrt allele were
associated with a high rate of therapeutic failures of chloroquine is
totally new. Several hypothesis may account for these findings.
First, a particular Pfcrt haplotype, restricted to the Malagasy area
and different from previously described resistant haplotypes, was
present but not detected during this study. As we sequenced for all
isolates a large part of Pfcrt gene including five codons consistently
associated with CQ resistance in other settings, this hypothesis
appears unlikely. It also is worth noting that so far the rare Pfcrt
mutant alleles found in two sites from Madagascar (Andapa and
Tsiroanomandidy) had a CVIET or CVIDT haplotype [25] and
most likely were imported from the neighbouring Comoros
Islands. Why did the CVIET haplotype not spread largely across
Madagascar in spite of a significant drug pressure, as it did in Asia
and Africa and even in the neighbouring Comoros Islands,
remains to explain. A second hypothesis is that another gene,
distinct from Pfcrt and not identified at present, is the main
responsible for CQ resistance in Madagascar. Though this
hypothesis cannot be formally ruled out, it appears also unlikely
in view of the observed, strong association with Pfmdr1. A third
possibility, is that the Pfcrt allele is present at a low fraction in the
time 0 sample, too low to be detected (masked by the wild type
allele and not detected by the PCR followed by DNA sequencing
methodology) and too low to translate into a shifted IC50 in vitro (as
these parasites represent a low fraction, they incorporate a low
amount of 3H hypoxanthine and remain unnoticed). We also
think this possibility unlikely, as no mutant Pfcrt could be detected
in the samples collected from patients with late therapeutic
failures. Indeed, the seminal studies by Djimde et al. in Mali
showed that the minority CQ resistant clone selected during a
treatment and causing a therapeutic failure accounted for a
substantial proportion of the parasites on the day of recurrence
[26]. Juliano et al. [27], using a nonradioactive heteroduplex
tracking assay, reported recently that in a unique series of 17
patients in Madagascar, two (11.7%) harboured Pfcrt CVIET-
resistant haplotype. The proportion of mutant parasites was 1.7
and 2.9% of the total parasite recurrent population obtained 14
days after the onset of CQ treatment, and neither of the two
patients harboured any detectable CVIET parasites prior to
treatment. In both cases the ‘‘recurrent’’ isolate 14 days after
treatment by CQ contained a vast majority of CQ susceptible
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PLoS ONE | www.plosone.org 5 October 2010 | Volume 5 | Issue 10 | e13281Figure 2. Prevalence of the two microsatellite loci flanking Pfmdr-1 gene. Distribution and prevalence of the two microsatellite loci flanking
Pfmdr-1 gene (MS 956456, panel A and MS 957861, panel B) in 53 Plasmodium falciparum isolates collected from Madagascar in 2006–2007.
doi:10.1371/journal.pone.0013281.g002
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genetic loci other than Pfcrt came into play in these recrudescences.
We did not detect any Pfcrt resistant haplotype on the recurrence
day of the 121 therapeutic failures of our series. Whether this
reflects a somewhat lower sensitivity of our methodology
compared to Juliano et al remains to be determined, but it is
certainly consistent with the conclusion that these recrudescences
are not associated with selection of a minority, mutant Pfcrt clone.
The fourth hypothesis is that mutant alleles of Pfmdr-1 play a major
role in CQ clinical outcome. Ten years ago, transfection methods
were used to explore the role of Pfmdr-1 mutations in CQ
resistance [28]. Introduction of wild-type polymorphisms into the
resistant 7G8 line resulted in reduction of CQ resistance but
introduction of mutations in the susceptible D10 line did not
confer CQ resistance, which suggested that Pfmdr-1 was not
sufficient by itself to confer resistance. Lessons drawn from a
recent genetic cross however indicate that observations with one or
the other P. falciparum line are not directly applicable to all lines
[24]. Different phenotypes of CQ resistance (and amodiaquine
resistance) exist in the world, differing in different geographical
Table 1. Univariate (conditional logistic regression) analysis of risks factors associated to CQ-treatment failure
(recrudescence), Madagascar, 2006–2007.
Exposure variables Treatment outcome
¥ P-value OR
# 95% CI

Failed Cured
n value n value
Collection sites
Epidemiological strata
1 Tropical (reference) 51 49.5% 52 50.5% 0.94* - -
Highlands 32 52.5% 29 47.5% 1.1 0.58–2.07
Sub-desert 38 50.0% 38 50.0% 1.0 0.55–1.80
EIR (number of bites of
infected anophelines per
person sleeping indoors)
2
,5 (reference)
.=5
70
51
51.1%
49.5%
67
52
48.9%
50.5%
0.89
1 -
0.95
-
0.57–1.60
Prevalence of anti-PfMSP-1
antibodies
3
,40% (reference)
.=40%
49
72
43.4%
56.7%
64
55
56.6%
43.3%
0.04
1 -
0.57
-
0.34–0.96
Patient characteristics
Male gender 121 44.3% 119 50.4% 0.2
1 0.78 0.47–1.30
Age mean (6 SD), year 121 4.8 (3.7) 119 7.03 (4.34) ,0.0001
{ 0.88 0.83–0.94
0.5–5 (reference) 79 64.8% 43 35.2% - - -
6–10 33 39.5% 49 60.5% 0.0005* 0.36 0.20–0.63
11–15 11 28.9% 27 71.1% 0.0002* 0.22 0.10–0.49
Temperature (uC) at day 0.
mean (6 SD)
121 38.4 (0.7) 119 38.3 (0.8) 0.61
{ 1.0824 0.80–1.47
Haemoglobin concentration
(g/dL) at Day 0.
mean (6 SD), g/dL
,10
.=10 (reference)
121
73
49
9.4 (2.4)
61.3
40.1
119
46
73
10.4 (2.1)
38.7%
59.9%
0.0002
{
0.001*
-
0.8
2.36
-
0.71–0.90
1.41–3.96
Previous CQ in-take (%) 121 8.2 119 8.4 0.57* 0.97 0.39–2.43
Clinical isolates
Parasitaemia density at Day 0
(no.of parasites/mL). mean (6 SD)
121 41,435
(60,928)
119 43,289
(55,338)
0.8
{ 1-
Multiplicity of infection
(MOI) mean. (6 SD)
121 1.9 (0.9) 119 1.7 (0.8) 0.06
{ 0.39 0.98–1.96
Pfmdr-1 86Y,% at Day 0 121 67.7% 119 52.9% 0.009
1 2.01 1.18–3.42
at Day of recrudescence
6 121 82.6% ,0.0001
1 4.23 2.34–7.65
Pfmdr-1 184F,% at Day 0 121 71.9% 119 71.4% 0.90
1 1.02 0.58–1.79
at Day of recrudescence
66 121 81.0% 0.08
1 1.70 0.93–3.11
Pfmdr-1 1246Y. % at Day 0 121 31.3% 119 31.9% 0.98
1 0.99 0.50–3.11
¥Treatment failure was based on the World Health Organization 28-day drug efficacy test and monitoring and corrected by PCR genotyping as described in Materials
ans Method section;
*Chi-squared test;
1Fisher exact test;
{ANOVA test (or if P-value of the Bartlett’s test for inequality of population variances was ,0.05, Mann–Whitney/Wilcoxon two-sample tests);
#OR: odds ratio;
"95% Confidence Interval;
6Discordant alleles found in 16 isolates between day 0 (wild-type NYD) and day of recrudescence (13 single-mutants YYD and 3 double-mutants YFD);
66Discordant alleles found in 8 additional isolates between day 0 (wild-type NYD) and day of recrudescence (8 single-mutants NFD);
1according to [18];
2according to [19] and
3according to [20].
doi:10.1371/journal.pone.0013281.t001
CQ Resistance in Madagascar
PLoS ONE | www.plosone.org 7 October 2010 | Volume 5 | Issue 10 | e13281Figure 3. Parasites curves following CQ-treatment according Pfmdr-1 alleles. Asexual parasites curves following CQ-treatment according
Pfmdr-1 mutation at position 86 in isolates from patients included in the analysis, Madagascar in 2006–2007.
doi:10.1371/journal.pone.0013281.g003
Figure 4. Curves of cumulative incidence of recurrence of patients over the 28-day follow-up period. Kaplan-Meier curves of cumulative
incidence of recurrence of patients over the 28-day follow-up period according Pfmdr-1 mutation at position 86 in isolates of day of recurrence from
patients included in the analysis, Madagascar in 2006–2007.
doi:10.1371/journal.pone.0013281.g004
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varies depending on the particular Pfcrt haplotype with which they
are associated [24].
The situation with regard to CQ resistance in Madagascar is
unique. There were high rates of therapeutic failures, but those
failures occurred in close to 90% of cases more than 7 days after
treatment (Late Treatment Failures, LTFs) whereas in sub-
Saharan Africa the proportion of LTFs is usually near 20%
[29,30,31,32,33]. The proportion of isolates with detectable Pfcrt
mutant parasites was totally disconnected from the rate of clinical
failures. Moreover, no selection of Pfcrt mutant haplotypes
between the first day of treatment and the day of recurrence
was observed, which contrasted strongly with studies conducted in
sub-Saharan countries [26]. We found also a selection of the N86Y
or Y184F mutant alleles between the first day of treatment and the
day of recurrence (10%), suggesting that Pfmdr-1 has a major role
in CQ clinical failures in Madagascar. However, this particular
type of resistance was not reliably detected by the classical isotopic
48-h test used in our study, as only 3.3% of isolates showed
phenotypic resistance (IC50.100 nM). The follow-up of circulat-
ing parasite densities over time in recurrent malaria episodes,
showing rapid (but not complete) asexual parasites clearance
within 72-hours following first day of treatment (Figure 3), was
consistent with the apparent in vitro susceptibility of the isolates
obtained in therapeutic failure cases. These results highlight the
limits of the in vitro tests routinely used to monitor the antimalarial
drug resistance. Based on the detection of the ‘‘trophozoites to
schizonts’’ growth during a single parasite erythrocytic cycle, it
appears that such in vitro assays can accurately detect high levels of
resistance (corresponding usually to early treatment failures) but
are unable to evaluate phenotypic resistance yielded by slow acting
molecular mechanisms (or unusual mechanism), likely related to
late failure treatments [23,34].
The analysis of microsatellites flanking Pfmdr-1 showed that
mutations occurred on multiple genetic backgrounds (Figure 2). As
previously described by Mehlotra et al. [9], we did not observe a
strong reduction of heterozygosity in the CQ resistant parasite
population, underlining that drug pressure from CQ treatment
exerts a weaker selection on Pfmdr-1 than on Pfcrt. This ‘‘soft’’
selection of Pfmdr-1 mutant alleles may also be due to quinine
pressure, as quinine was for a long time and until recently the
antimalarial most commonly prescribed by practitioners in
Madagascar [12]. The spread of Pfmdr-1 mutant alleles may
reflect a better fitness of parasites harbouring them or a better
efficacy of the transmission [35].
Apart from the Pfmdr-1N86Y allele, the main risk factors
associated with CQ therapeutic failures, lower age and lower
prevalence of anti-PfMSP-1 antibodies, were inversely correlated
with the immune status of patients. These results are similar with
what has been reported for Pfcrt mutants in Mali and other
countries where increasing age, reflecting the progressive acqui-
sition of partial immunity, helped in the clearance of resistant
parasites [26]. Hence, the immune status of patients probably
explains why a significant proportion of patients having isolates
harbouring a mutant Pfmdr-1 allele were successfully cured by CQ
in our series.
At present, CQ is being replaced by newer artemisinin-based
combination drugs, such as artesunate-amodiaquine as first-line
treatment in uncomplicated falciparum malaria in Madagascar. As
Pfmdr-1 is a major modulator of resistance to these drugs [10],
monitoring in the future in which measure the high proportion of
Pfmdr-1 mutants observed in Madagascar can have an impact on
the resistance of these antimalarials, even if at the moment this
impact seems modest [11]. More generally, gaining insight about
the mechanisms that regulate the genetic variation at Pfmdr1 is
important, particularly regarding the evolution and spread of
Pfmdr-1 alleles in P. falciparum populations under changing drug
pressure which may have important consequences in terms of
antimalarial use management.
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